JP2013507132A5 - - Google Patents

Download PDF

Info

Publication number
JP2013507132A5
JP2013507132A5 JP2012533384A JP2012533384A JP2013507132A5 JP 2013507132 A5 JP2013507132 A5 JP 2013507132A5 JP 2012533384 A JP2012533384 A JP 2012533384A JP 2012533384 A JP2012533384 A JP 2012533384A JP 2013507132 A5 JP2013507132 A5 JP 2013507132A5
Authority
JP
Japan
Prior art keywords
isolated polypeptide
binding
polypeptide
amino acids
group
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2012533384A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013507132A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2010/052194 external-priority patent/WO2011044563A2/en
Publication of JP2013507132A publication Critical patent/JP2013507132A/ja
Publication of JP2013507132A5 publication Critical patent/JP2013507132A5/ja
Pending legal-status Critical Current

Links

JP2012533384A 2009-10-10 2010-10-11 Ｉｌ−１７ファミリーサイトカイン組成物及び使用 Pending JP2013507132A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US27877909P 2009-10-10 2009-10-10
US61/278,779 2009-10-10
PCT/US2010/052194 WO2011044563A2 (en) 2009-10-10 2010-10-11 Il-17 family cytokine compositions and uses

Publications (2)

Publication Number Publication Date
JP2013507132A JP2013507132A (ja) 2013-03-04
JP2013507132A5 true JP2013507132A5 (enExample) 2013-11-28

Family

ID=43857433

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2012533384A Pending JP2013507132A (ja) 2009-10-10 2010-10-11 Ｉｌ−１７ファミリーサイトカイン組成物及び使用

Country Status (11)

Country Link
US (1) US20130064788A1 (enExample)
EP (1) EP2485763A4 (enExample)
JP (1) JP2013507132A (enExample)
KR (1) KR20120093932A (enExample)
CN (1) CN102648002A (enExample)
AU (1) AU2010303166A1 (enExample)
BR (1) BR112012008444A2 (enExample)
CA (1) CA2777222A1 (enExample)
EA (1) EA201270528A1 (enExample)
IL (1) IL219209A0 (enExample)
WO (1) WO2011044563A2 (enExample)

Families Citing this family (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7833527B2 (en) 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
SG172789A1 (en) 2009-02-11 2011-08-29 Novozymes Biopharma Dk As Albumin variants and conjugates
BR112012009450A2 (pt) 2009-10-30 2017-05-23 Novozymes Biopharma Dk As variantes de albumina
EP2556087A1 (en) 2010-04-09 2013-02-13 Novozymes Biopharma DK A/S Albumin derivatives and variants
CN107337735B (zh) 2010-07-29 2021-06-22 巴扎德制药公司 嵌合il-1受体i型激动剂和拮抗剂
WO2012138977A1 (en) * 2011-04-06 2012-10-11 Board Of Trustees Of The Leland Stanford Junior University Structural based design of il-17 dominant negative mutants
WO2013016220A1 (en) * 2011-07-22 2013-01-31 Amgen Inc. Il-17 receptor a is required for il-17c biology
HUE037087T2 (hu) * 2011-10-19 2018-08-28 Morphosys Ag IL17C antagonistái gyulladásos rendellenességek kezelésére
US20140314798A1 (en) * 2011-10-21 2014-10-23 Baylor College Of Medicine Method to measure inflammation in the conjunctiva of patients with tear dysfunction
EP2780364A2 (en) 2011-11-18 2014-09-24 Eleven Biotherapeutics, Inc. Proteins with improved half-life and other properties
ES2664328T3 (es) 2012-03-16 2018-04-19 Albumedix A/S Variantes de albúmina
JP2013253842A (ja) * 2012-06-06 2013-12-19 Univ Of Tokyo ｐＨ依存的に標的分子に結合するペプチドのスクリーニング方法
WO2013186236A1 (en) * 2012-06-12 2013-12-19 Orega Biotech Antagonists of il-17 isoforms and their uses
EP3417878A1 (en) * 2012-06-12 2018-12-26 Orega Biotech Antagonists of il-17 isoforms and their uses
CA2890766A1 (en) 2012-11-08 2014-05-15 Novozymes Biopharma Dk A/S Albumin variants
PL2968468T3 (pl) 2013-03-13 2021-12-20 Buzzard Pharmaceuticals AB Preparaty chimerycznej cytokiny do dostarczania do oka
EP2986310B1 (en) * 2013-04-17 2020-08-05 Genzyme Corporation Compositions for treating and preventing macular degeneration
AR103173A1 (es) 2014-12-22 2017-04-19 Novarits Ag Productos farmacéuticos y composiciones líquidas estables de anticuerpos il-17
CA2989966C (en) 2015-08-20 2024-04-30 Albumedix A/S Albumin variants and conjugates
EP4194007B1 (en) * 2016-03-25 2025-08-13 The University of Osaka Conjugate vaccine targeting disorder-causing in vivo protein
US20200179305A1 (en) * 2016-04-19 2020-06-11 Azura Ophthalmics Ltd. Compositions for the Treatment of Hyperkeratosis Disorders
WO2019018652A1 (en) * 2017-07-21 2019-01-24 The Cleveland Clinic Foundation SBE APTAMERS FOR THE TREATMENT OF DISEASES AND CONDITIONS ASSOCIATED WITH IL-17A
DK3794024T5 (da) 2018-05-14 2024-08-19 Werewolf Therapeutics Inc Aktiverbare interleukin-2 polypeptider og fremgangsmåder til anvendelse heraf
EP3794023A1 (en) 2018-05-14 2021-03-24 Werewolf Therapeutics, Inc. Activatable interleukin 12 polypeptides and methods of use thereof
US20220175815A1 (en) 2019-04-03 2022-06-09 Orega Biotech Combination therapies based on pd1 and il-17b inhibitors
MX2021013766A (es) 2019-05-14 2022-02-21 Werewolf Therapeutics Inc Restos de separacion y metodos de uso de los mismos.
EP4007775A1 (en) * 2019-08-02 2022-06-08 Orega Biotech Novel il-17b antibodies
KR102265435B1 (ko) * 2019-08-20 2021-06-15 주식회사 케어젠 피부 미백 활성을 갖는 펩타이드 및 이의 용도
AU2020384375A1 (en) 2019-11-14 2022-05-26 Werewolf Therapeutics, Inc. Activatable cytokine polypeptides and methods of use thereof
EP4087655A4 (en) 2020-01-10 2024-02-21 Azura Ophthalmics Ltd INSTRUCTIONS FOR COMPOSITION AND SENSITIVITY
US20230045494A1 (en) 2020-02-28 2023-02-09 Orega Biotech Combination therapies based on ctla4 and il-17b inhibitors
WO2022032592A1 (en) * 2020-08-13 2022-02-17 Tsinghua University Interleukin-17d and cd93 as a new cytokine-receptor pair in the immune system
CN113403259B (zh) * 2021-06-04 2023-01-17 华南农业大学 一种提高克隆胚胎发育质量的添加剂及其应用
CN113563453A (zh) * 2021-07-23 2021-10-29 四川大学 鸡白细胞介素17b重组乳酸菌免疫制剂的制备和应用

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
JP4373495B2 (ja) * 1995-03-23 2009-11-25 イミュネックス・コーポレーション Ｉｌ−１７受容体
US6569419B2 (en) * 2000-02-29 2003-05-27 Zymogenetics, Inc. Methods for promoting production of myelin by Schwann cells
US20030203451A1 (en) * 2000-08-24 2003-10-30 Genentech, Inc. IL-17 homologous polypeptides and therapeutic uses thereof
US6333410B1 (en) 2000-08-18 2001-12-25 Immunogen, Inc. Process for the preparation and purification of thiol-containing maytansinoids
WO2002033083A2 (en) * 2000-10-13 2002-04-25 Eli Lilly And Company Methods of using a human il-17-related polypeptide to treat disease
JP2004517918A (ja) * 2000-10-18 2004-06-17 イミュネックス・コーポレーション Ｉｌ−１７アンタゴニストを使用する慢性関節リューマチの治療法
EP1328260A2 (en) 2000-10-18 2003-07-23 Massachusetts Institute Of Technology Methods and products related to pulmonary delivery of polysaccharides
US20040115191A1 (en) * 2002-01-24 2004-06-17 Moore Emma E Method for treating psoriasis
CA2452233A1 (en) * 2001-03-26 2002-10-03 Zymogenetics, Inc. Method of inducing proliferation of retinal stem cells
US20070160576A1 (en) * 2001-06-05 2007-07-12 Genentech, Inc. IL-17A/F heterologous polypeptides and therapeutic uses thereof
US20040142325A1 (en) * 2001-09-14 2004-07-22 Liat Mintz Methods and systems for annotating biomolecular sequences
US20040132101A1 (en) 2002-09-27 2004-07-08 Xencor Optimized Fc variants and methods for their generation
ES2424353T3 (es) * 2003-07-08 2013-10-01 Genentech, Inc. Polipéptidos heterólogos IL-17 A/F y usos terapéuticos de los mismos
GB0417487D0 (en) * 2004-08-05 2004-09-08 Novartis Ag Organic compound
CA2638864A1 (en) * 2006-02-10 2007-10-18 Zymogenetics, Inc. Truncated il-17ra soluble receptor and methods of using in inflammation
CA2646478A1 (en) * 2006-03-10 2007-09-20 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
GB0612928D0 (en) * 2006-06-29 2006-08-09 Ucb Sa Biological products
CA2660463C (en) * 2006-08-11 2013-07-16 Schering Corporation Antibodies to il-17a
US7833527B2 (en) * 2006-10-02 2010-11-16 Amgen Inc. Methods of treating psoriasis using IL-17 Receptor A antibodies
US7790676B2 (en) 2007-03-28 2010-09-07 Zymogenetics, Inc. Soluble IL-17RA/RC fusion proteins
US8460647B2 (en) * 2007-04-20 2013-06-11 Amgen Inc. Pre-ligand assembly domain of the IL-17 receptor
WO2008133684A1 (en) * 2007-04-27 2008-11-06 Zymogenetics, Inc. Antibodies that bind both il-17a and il-17f and methods of using the same
EP2182943B1 (en) * 2007-07-23 2016-10-26 Janssen Biotech, Inc. Methods and compositions for treating fibrosis related disorders using il-17 antagonists

Similar Documents

Publication Publication Date Title
JP2013507132A5 (enExample)
JP2010519252A5 (enExample)
JP2011136981A5 (enExample)
JP2010534684A5 (enExample)
JP2017048194A5 (enExample)
JP2010088434A5 (enExample)
JP2013539454A5 (enExample)
JP2011155981A5 (enExample)
RU2017104529A (ru) Композиции neisseria meningitidis и способы их применения
JP2012126742A5 (enExample)
JP2010166916A5 (enExample)
JP2012034696A5 (enExample)
CY1119265T1 (el) Κατασκευες νανοσωματων τρισθενους αντι ανθρωπινου αναπνευστικου συγκυτιακου ιου (hrsv) για την προληψη και/ή θεραπεια λοιμωξεων της αναπνευστικης οδου
JP2014525439A5 (enExample)
JP2010065037A5 (enExample)
NZ593550A (en) ANTI-Siglec-15 ANTIBODY
JP2013510581A5 (enExample)
JP2014028813A5 (enExample)
JP2012512213A5 (enExample)
JP2012520430A5 (enExample)
UA110118C2 (uk) Мікобактеріальна антигенна композиція
JP2009256608A5 (enExample)
JP2015533791A5 (enExample)
JP2012255007A5 (enExample)
JP2009504138A5 (enExample)